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Abstract
To identify the presence of a local kallikrein^kinin system in vascular wall, we have studied whether rat vascular smooth
muscle cells (VSMC) express kininogen in vitro and in vivo. Western blots using anti-T-kininogen antibody revealed the
presence of T-kininogen in conditioned medium of cultured VSMC. T-Kininogen secretion by VSMC was markedly
enhanced by the addition of lipopolysaccharide (LPS), angiotensin II (AII) and phorbol 12-myristate 13-acetate (PMA) to
the culture. Experiments using specific inhibitors for protein kinases and on the PMA-induced down-regulation of protein
kinase C suggested that a protein kinase C-dependent or unidentified pathway is involved in AII or LPS action, respectively.
The intravenous injection of LPS (0.5 mg/kg) resulted in an increase in T-kininogen mRNA levels in the vascular smooth
muscle of rat aorta, peaking at 16 h. Polyacrylamide gel electrophoresis of cDNA products generated by reverse
transcription^polymerase chain reaction (RT^PCR) from aortic mRNA using primers specific for either T- or low-
molecular-weight kininogen revealed that rat vascular smooth muscle expressed T-kininogen gene but not low-molecular-
weight kininogen gene, and that LPS exclusively stimulated T-kininogen expression. The mRNA for high-molecular-weight
kininogen was undetectable in either aortic smooth muscle or cultured VSMC by means of RT^PCR analysis. RT^PCR
using specific primers for rat tissue kallikrein genes showed that aortic smooth muscle expressed KLK1 (true kallikrein)
mRNA, but not KLK10 (T-kininogenase) mRNA. These results demonstrated that rat VSMC are a source of T-kininogen
but not of low-molecular-weight- or high-molecular-weight kininogen, in contrast to the expression of true kallikrein
but not of T-kininogenase by these cells. 0167-4889 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The vascular tissues have been recognized as an
endocrine and paracrine organ with a variety of
functions involved in the regulation of blood pres-
sure. The kallikrein^kinin system is one of the endog-
enous vasodepressor systems regulating blood pres-
sure and generates potent vasodilating peptides,
kinins, by a proteolytic activity of kallikreins on spe-
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Abbreviations: VSMC, vascular smooth muscle cells ; LMW-
kininogen, low-molecular-weight kininogen; HMW-kininogen,
high-molecular-weight kininogen; RT^PCR, reverse transcrip-
tion^polymerase chain reaction; LPS, lipopolysaccharide; AII,
angiotensin II; Bt2cAMP, dibutyryl cyclic AMP; PMA, phorbol
12-myristate 13-acetate; IL-1, interleukin-1; IL-6, interleukin-6;
TNF, tumor necrosis factor; HBSS, Hanks’ bu¡ered salt solu-
tion; DME, Dulbecco’s modi¢ed Eagle’s medium; FBS, fetal
bovine serum
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ci¢c substrates kininogens [1]. The existence of an
endogenous kallikrein^kinin system within the vascu-
lar wall [2] is supported by the following evidence:
kallikrein is present in and is released from rat vas-
cular tissue [3] or vascular smooth muscle cells
(VSMC) in culture [4], rat VSMC contain mRNA
for glandular kallikrein [5], and rat VSMC secrete
a kininogen-like protein which releases a kinin on
trypsin digestion [4]. This evidence suggests that
both glandular kallikrein and kininogen are supplied
locally within the vascular wall. However, no further
characterization of the kallikrein^kinin system in
vascular tissues has been reported.
The purpose of the present study was to clarify
which species of kininogens is expressed by rat
VSMC and what kinds of factors regulate the expres-
sion. Our results showed that a major kininogen syn-
thesized by rat VSMC was T-kininogen, and that the
synthesis was stimulated by lipopolysaccharide (LPS)
and angiotensin II (AII).
2. Materials and methods
2.1. Materials
The following chemicals were obtained from com-
mercial sources: LPS (Staphylococcus typhosa 0901)
from Difco (Detroit, MI, USA); AII and bradykinin
from Peptide Institute (Osaka, Japan); dibutyryl
cyclic AMP (Bt2cAMP) from Boehringer-Mann-
heim-Yamanouchi (Tokyo, Japan); phorbol 12-myr-
istate 13-acetate (PMA) from Nacalai tasque (Kyoto,
Japan); Immobilon-PSQ membrane from Millipore;
recombinant mouse interleukin-6 (IL-6; 1U108
U/mg) from Genzyme; H-7, H-89 and W-7 from
Funakoshi (Tokyo); and monoclonal anti-K-smooth
muscle actin^alkaline phosphatase conjugate from
Sigma. Recombinant human interleukin-1K (IL-1;
2U107 U/mg) and tumor necrosis factor-K (TNF;
3U106 U/mg) were donated by Dainippon Pharma-
ceutical (Osaka, Japan).
2.2. Isolation of smooth muscle and VSMC from rat
aorta
Sprague^Dawley male rats, weighing 140^160 g,
were anesthetized with ether and decapitated. Thor-
atic aorta (about 5 cm) were removed, and placed in
a petri dish containing ice-cold Hanks’ bu¡ered salt
solution (HBSS). The aorta was rinsed several times
with HBSS, stripped of adventitia and denuded of
endothelium with forceps. VSMC were grown from
the explants of aorta without endothelium and were
cultured in Dulbecco’s modi¢ed Eagle’s medium
(DME) containing 15% fetal bovine serum (FBS).
They were passaged every 10 days by harvesting
with trypsin/EDTA and seeding at a 1:5 ratio in
28-cm2 dishes. For experiments, cells after three to six
passages were seeded into 75-cm2 dishes or 24-well cul-
ture plates, fed every other day, and used at con£uence
(5^10 days). More than 95% of cells were positively
stained with monoclonal anti-K-smooth muscle ac-
tin^alkaline phosphatase conjugate. Established
smooth muscle cell line A7r5 cells, originating from
the embryonic thoracic aorta of a DB1X rat, were ob-
tained from Dainippon Pharmaceutical (Osaka,
Japan) and maintained in DME containing 15% FBS.
2.3. Western blots of T-kininogen
VSMC in a 75-cm2 dish at con£uence were washed
three times with FBS-free DME, then cultured in
FBS-free DME for 3 days. Conditioned medium
was harvested, dialyzed thoroughly against distilled
water at 4‡C, then lyophilized. The lyophilized sam-
ple was resolved by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis in a 10% gel according to
the method of Laemmli [6]. The resolved proteins
were electrophoretically transferred to a nitrocellu-
lose membrane, which was then blocked with 10%
skimmed milk before being incubated with rabbit
anti-rat T-kininogen antibody. Rabbit IgG on the
membrane was detected by the avidin^biotin^perox-
idase complex method according to the instruction
manual issued by Bio-Rad Laboratories.
2.4. Detection of kininogen mRNAs in smooth muscle
or VSMC of rat aorta
Expressions of kininogen mRNAs in smooth
muscle or VSMC of rat aorta were determined by
reverse transcription^polymerase chain reaction
(RT^PCR) followed by Southern blotting using
T-kininogen cDNA or high-molecular-weight
(HMW) kininogen cDNA as a probe, as follows.
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Total RNA was extracted with acid guanidinium^
phenol^chloroform [7] from isolated smooth muscle
or cultured VSMC. Total RNA (1 Wg) was reverse
transcribed in a 20 Wl reaction mixture containing
50 pmol of the reverse primer, 2 Wl of 10 mM
dNTP, 2 Wl of 10UPCR bu¡er (0.1 M Tris^HCl
(pH 8.3), 500 mM KCl), 4 Wl of 25 mM MgCl2,
1 unit of RNase inhibitor, and 1 unit of cloned Mo-
loney murine leukemia virus reverse transcriptase
(GeneAmp RNA PCR kit; Takara, Japan). The
RT reaction mixture was incubated at 42‡C for
15 min, 99‡C for 5 min, then 5‡C for 5 min to allow
synthesis of the ¢rst strand of cDNA. The cDNA
was ampli¢ed in a 100 Wl reaction mixture containing
50 pmol of the forward primer, 8 Wl of 10UPCR
bu¡er, 4 Wl of 25 mM MgCl2, and 2.5 units of Taq
DNA polymerase. Eighteen to 25 cycles proceeded as
follows: denaturation at 95‡C for 1 min, annealing at
53‡C for 2 min and extension at 72‡C for 3 min. RT^
PCR products (5 Wl) were Southern blotted and auto-
radiographed using a Fuji Film Bio Imaging Ana-
lyzer BAS1000 (Fuji Film, Tokyo). We designed a
set of primers common to both T- and low-molecu-
lar-weight (LMW) kininogen cDNAs, because the
structures of these kininogen cDNAs are highly ho-
mologous [8]. The forward and reverse primers for
both T- and LMW-kininogen cDNAs were 5P-
ACATCACAGGTGGTTGCTGGA-3P (nucleotides
961^981) and 5P-AGTACAAGGGCAGACTCTCA-
3P (nucleotides 1256^1275), respectively. The forward
and reverse primers for HMW-kininogen were 5P-
TACATGAGACCTTGGGAGAA-3P (nucleotides
1105^1124) and 5P-AGTCCTGAAAACCACGA-
GAG-3P (nucleotides 1701^1720), respectively. The
probe for Southern hybridization of T-kininogen or
HMW-kininogen was a 702-bp Sau3A1 fragment of
T-kininogen cDNA [8] or a 616-bp fragment of
HMW-kininogen cDNA, respectively.
2.5. Separation and detection of T- and
LMW-kininogen mRNAs
To analyze RT^PCR products of T- and LMW-
kininogen mRNAs, we used a £uorophore Cy5-la-
beled 5P-primer (Pharmacia) for RT^PCR, then the
ampli¢ed cDNA products were separated and de-
tected using an ALFred DNA sequencer (Pharmacia)
as follows. RT^PCR was carried out with a Cy5-
labeled 5P-primer as described above, then the prod-
uct (1 Wl) was mixed with 6 Wl distilled water and 5 Wl
formamide, and heated at 95‡C for 5 min. A sample
(1 Wl) was then electrophoresed on a denatured poly-
acrylamide gel containing 5% acrylamide and 42%
urea using a DNA sequencer. Elutions of Cy5-la-
beled cDNA products were monitored by a £uoro-
detector of the sequencer. The retention times for
T- and LMW-kininogen cDNA products were deter-
mined by the electrophoretic pro¢le of RT^PCR
products from authentic T- or LMW-kininogen
cRNA. cRNAs were prepared using SP6/T7 Tran-
scription Kit (Boehringer-Mannheim, Tokyo) from
respective cDNAs that had been cloned from RT^
PCR products of rat liver using TA Cloning Kit
(Invitrogen, CA, USA).
2.6. Detection of tissue kallikreins KLK1 and KLK10
mRNAs in smooth muscle or VSMC of rat aorta
Expressions of KLK1 (true kallikrein) and KLK10
(T-kininogenase) mRNAs in aorta muscle or VSMC
were determined by RT^PCR followed by Southern
blotting, using speci¢c primers and probes as de-
scribed by McDonald et al. [9].
2.7. T-Kininogen radioimmunoassay
T-Kininogen was measured by radioimmunoassay
using 125I-labeled T-kininogen and rabbit anti-T-ki-
ninogen antibody, as described previously [10].
2.8. Statistical analysis
Results are presented as means þ S.D. The statisti-
cal signi¢cance of the di¡erence between means was
determined by Student’s t-test.
3. Results
3.1. Identi¢cation of T-kininogen in conditioned
medium of cultured VSMC
It is well documented that rat plasma contains
three species of kininogens, HMW-, LMW- and T-
kininogens, of which T-kininogen is a major kinino-
gen produced by various tissues [11,12]. Thus we ¢rst
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investigated whether the culture medium of rat
VSMC contained a material that was reactive with
a rabbit anti-T-kininogen antibody. Western blotting
demonstrated that the conditioned medium con-
tained a single immunoreactive band that was indis-
tinguishable from rat plasma T-kininogen corre-
sponding to a molecular mass of 68 kDa (Fig. 1).
When Western blotting was carried out using a pre-
immune rabbit serum, neither the conditioned me-
dium of VSMC nor puri¢ed T-kininogen revealed
any immunoreactive bands (data not shown). T-Ki-
ninogen-like immunoreactivity was detected in the
conditioned medium after 72 h culture at a level of
19.2 þ 13.2 ng/mg cell protein (n = 4) by radioimmu-
noassay.
3.2. E¡ect of various agents on T-kininogen secretion
by VSMC
We recently reported that T-kininogen synthesis
was enhanced by Bt2cAMP and cytokines, such as
IL-1 and TNF in rat ¢broblasts [13]. To determine
which factors regulate T-kininogen synthesis by
VSMC, cells were cultured for 72 h with Bt2cAMP,
AII, LPS, PMA, or cytokines, such as TNF, IL-1,
IL-6. T-Kininogen secretion by VSMC was markedly
stimulated by AII (1 WM), LPS (5 Wg/ml) and PMA
(10 nM), while not a¡ected by Bt2cAMP (1 mM) and
cytokines (500 U/ml) (Fig. 2). Lower concentrations
of AII (10 nM) and LPS (0.5 Wg/ml) were also e¡ec-
tive in stimulating T-kininogen secretion (data not
shown). Pretreatment of the cells with 0.1 WM
PMA for 24 h abolished the stimulatory e¡ect of
AII, LPS and PMA on T-kininogen secretion (Fig.
3). To examine the role of protein kinases in AII- or
LPS-induced T-kininogen response, cells were prein-
cubated with protein kinase inhibitors H-7 (30 WM),
H-89 (5 WM) or W-7 (70 WM) for 1 h. As shown in
Fig. 4, AII-induced enhancement of the VSMC T-
kininogen response was suppressed by H-7, but not
by H-89 and W-7, while the e¡ect of LPS was inhib-
ited by these inhibitors to a similar extent.
Fig. 2. The e¡ects of various agents on the secretion of T-kini-
nogen by rat VSMC. Rat VSMC were cultured in 24-well plates
with or without various agents for 3 days, and the T-kininogen
in the medium was assayed by T-kininogen radioimmunoassay.
The results are expressed as the means þ S.D. of four wells. Un-
treated cells secreted 19.2 þ 13.2 ng/mg cell protein for 3 days’
culture. Agents: tumor necrosis factor-K (TNF; 500 U/ml); in-
terleukin-1K (IL-1; 500 U/ml); interleukin-6 (IL-6; 500 U/ml);
dibutyryl cyclic AMP (Bt2cAMP; 1 mM); lipopolysaccharide
(LPS; 5 Wg/ml); angiotensin II (AII; 1 WM); 12-myristate
13-acetate (PMA; 10 nM). Statistical analysis in comparison to
unstimulated culture: *P6 0.001.
Fig. 1. Western blots of T-kininogen-like immunoreactive mate-
rial in the conditioned medium of rat vascular smooth muscle
cells (VSMC). Rat VSMC were cultured for 3 days, then the
conditioned medium was harvested, dialyzed against distilled
water and lyophilized. The rat T-kininogen (lane 1), rat serum
(2 Wl ; lane 2) and lyophilized sample (lane 3) were resolved by
sodium docecyl sulfate^polyacrylamide gel electrophoresis in a
10% gel and transferred to nitrocellulose membrane. The blot
was incubated with anti-T-kininogen antibody followed by goat
biotinylated anti-rabbit IgG, then with horseradish-labeled avi-
din. The numbers to the right of the blot represent molecular
mass standards in kDa.
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3.3. Expression of T-kininogen mRNA in rat VSMC
Expression of T-kininogen mRNA in VSMC in
vitro and in vivo was determined by RT^PCR fol-
lowed by Southern blotting using T-kininogen cDNA
as a probe. As shown in the representative autora-
diogram in Fig. 5, a signal corresponding to the size
of T-kininogen cDNA was faint in non-treated
VSMC in vitro. However, the signal became intense
Fig. 5. Southern blot analysis of cDNA products from cultured rat VSMC (A) and A7r5 cells (B) generated by reverse transcription^
polymerase chain reaction (RT^PCR) using primers and probe speci¢c for T-kininogen. (A) Rat VSMC were cultured with LPS
(0.5 Wg/ml) or AII (1 WM) for several hours. (B) A7r5 cells were cultured with or without LPS (0.5 Wg/ml) for 24 h. RT^PCR
(25 cycles) for T-kininogen mRNA was performed with total RNA (1 Wg) extracted from cells, then Southern blotting of the cDNA
products was carried out using T-kininogen cDNA as a probe. The bottom panel shows Southern blots of the RT^PCR products am-
pli¢ed (20 cycles) by speci¢c primers and probe for glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA. Experiments were car-
ried out four times for each treatment, and representative results were shown.
Fig. 4. E¡ects of protein kinase inhibitors on the AII- or LPS-
induced secretion of T-kininogen by rat VSMC. Rat VSMC
were incubated with or without protein kinase inhibitors H-7
(30 WM), H-89 (5 WM) or W-7 (70 WM) for 1 h, then cultured
for 3 days following the addition of AII (1 WM) or LPS (5
Wg/ml). T-Kininogen in the medium was assayed by means of a
T-kininogen radioimmunoassay. The results are expressed as
the means þ S.D. of four wells. Statistical analysis in compari-
son with the culture with AII alone or LPS alone, respectively:
*P6 0.001.
Fig. 3. E¡ects of PMA pretreatment on the LPS-, AII- or
PMA-induced secretion of T-kininogen by rat VSMC. Rat
VSMC were cultured for 1 day with 0.1 WM PMA. Cells were
washed three times with fresh medium, then cultured with LPS
(5 Wg/ml), AII (1 WM) or PMA (10 nM) for 3 days, and T-kini-
nogen in the medium was assayed by means of a T-kininogen
radioimmunoassay. The results are expressed as the
means þ S.D. of four wells. Statistical analysis in comparison to
unstimulated culture: *P6 0.001.
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in the cells that had been cultured with LPS (0.5
Wg/ml) or AII (1 WM), and peaked at 16^24 h after
the treatment. An aortic smooth muscle cell line
(A7r5) also expressed T-kininogen mRNA, and the
expression was enhanced by an addition of LPS
(0.5 Wg/ml) in the culture (Fig. 5).
A marked induction of T-kininogen mRNA was
also found in rat aorta in vivo after an intravenous
injection of LPS (0.5 mg/kg) (Fig. 6). However, nei-
ther the intravenous bolus injection of AII (100 ng/
animal) nor the continuous infusion of AII (50 ng/
min) for 24 h by the subcutaneously implanted os-
motic minipump in£uenced the levels of T-kininogen
mRNA in the aorta (data not shown).
3.4. Expression of LMW-kininogen mRNA in rat
aorta
It is well documented that T-kininogen is highly
homologous to LMW-kininogen [8]. Since the pri-
mers used in this study for detecting T-kininogen
mRNA could also amplify LMW-kininogen cDNA
[14], it was conceivable that the RT^PCR products
of VSMC were a mixture of T- and LMW-kininogen
cDNAs. To determine this possibility, a RT^PCR
was carried out using a £uorescent Cy5-labeled 5P-
primer for both T- and LMW-kininogen cDNAs,
then separation and detection of labeled cDNA
products were performed with an ALFred DNA se-
quencer (Pharmacia) on the basis of a 6 bp di¡erence
in cDNA products between T- (315 bp) and LMW-
(321 bp) kininogens [14]. Fig. 7 shows a representa-
tive electrogram in which the retention time for au-
thentic T-kininogen cDNA was shorter than that for
LMW-kininogen cDNA. The RT^PCR products of
aorta collected from the non-treated rats revealed a
faint peak corresponding to T-kininogen cDNA,
whereas there was no peak corresponding to
LMW-kininogen cDNA. The samples from LPS-
treated rats showed a clear large peak of T-kininogen
cDNA, but no peak was found at the retention time
of LMW-kininogen cDNA. Thus it is likely that rat
VSMC do not express LMW-kininogen gene, and
that LPS stimulates the expression of T-kininogen
gene but not that of LMW-kininogen gene.
Fig. 7. Electrophoresis and detection of RT^PCR products of
T- and LMW-kininogen mRNAs in the rat aortic smooth
muscle by DNA sequencer. Total RNA samples were prepared
from aortic smooth muscle of untreated or LPS-pretreated rats
(24 h, 0.5 mg/kg, i.v.). The cDNAs transcribed from these sam-
ples were ampli¢ed by 18 cycles using a £uorescence-labeled
5P-primer and non-labeled 3P-primer which were speci¢c for
both T- and LMW-kininogen cDNAs. The labeled products
were resolved by polyacrylamide gel electrophoresis and ana-
lyzed using an ALFred DNA sequencer (Pharmacia). The reten-
tion times for authentic T-kininogen and LMW-kininogen
cDNAs were 263 and 269 min, respectively. Experiments were
carried out with RNA samples from four non-treated and four
LPS-treated animals, and representative results are shown.
Fig. 6. Southern blot analysis of cDNA products generated
from rat aortic smooth muscle by RT^PCR using primers and
probe speci¢c for T-kininogen. Rats were injected with LPS
(0.5 mg/kg, i.v.), then four rats each were killed at 4, 8, 16, and
24 h by bleeding under ether anesthesia. Four untreated ani-
mals were killed as a control group. Thoracic aorta was iso-
lated and the endothelium was denuded. Total RNA of aortic
smooth muscle was extracted, and 1 Wg the sample was ana-
lyzed by RT^PCR followed by Southern blotting, as described
in Fig. 5. Representative Southern blottings are shown.
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3.5. Expression of HMW-kininogen mRNA in rat
aorta
To determine if rat VSMC express HMW-kinino-
gen, total RNA samples from aortic smooth muscle
were examined by RT^PCR followed by Southern
blotting using HMW-kininogen cDNA as a probe.
We could not detect a signal corresponding to
HMW-kininogen cDNA in the aortic muscle of ei-
ther non-treated or LPS-treated rats nor in the cul-
tured VSMC, in contrast to a distinct signal of
HMW-kininogen cDNA in rat liver (data not
shown).
3.6. Expression of tissue kallikrein mRNA in rat aorta
To determine whether rat aorta synthesizes T-kini-
nogenase which is able to liberate T-kinin (Ile-Ser
bradykinin) from T-kininogen [15], RNA samples
from rat aortic smooth muscle were subjected to
RT^PCR using speci¢c primers for rKLK10 (T-kini-
nogenase) mRNA [9]. On Southern blotting, RT^
PCR-ampli¢ed samples from rat submandibular
gland RNA hybridized to the rKLK10 probe, reveal-
ing an ampli¢ed 250-bp fragment, whereas no signal
could be observed with RNA samples from aorta
muscle and cultured VSMC (Fig. 8). No signal of
rKLK10 mRNA was also observed in RNA samples
from aorta muscle of LPS-treated rats (0.5 mg/kg,
i.v., 24 h) and those from VSMC that had been cul-
tured with LPS (0.5 Wg/ml) for 24 h (data not
shown). In contrast, an ampli¢ed 347-bp fragment
was observed by RT^PCR using primers speci¢c
for rKLK1 (true kallikrein) with RNA samples
from both aorta muscle and submandibular gland
(Fig. 8).
4. Discussion
Western blotting using anti-T-kininogen antibody
showed that primary cultures of rat VSMC secreted
T-kininogen-like protein in culture medium. How-
ever, since the structure of T-kininogen is highly ho-
mologous to that of rat LMW-kininogen [8], a pos-
sibility that the polyclonal antibody recognized
LMW-kininogen as well as T-kininogen could not
be excluded. Furthermore, primers for detecting T-
kininogen mRNA by RT^PCR were speci¢c for re-
gions common to both T- and LMW-kininogen
genes, indicating that the ampli¢ed fragments were
a mixture of products derived from these genes. To
determine whether rat VSMC express T- and/or
LMW-kininogen, we measured relative amounts of
RT^PCR products ampli¢ed from T- and LMW-ki-
ninogen mRNAs by separating and detecting these
products on polyacrylamide gel electrophoresis [14].
We found a high level of T-kininogen cDNA in the
RT^PCR products from the aorta muscle of LPS-
treated rats, whereas there was an undetectable level
of LMW-kininogen cDNA in the tissue of either
non- or LPS-treated rats. We also attempted to de-
tect HMW-kininogen mRNA in rat VSMC by means
of the RT^PCR, but found no signal. Thus it is
reasonable to conclude that rat VSMC express T-
kininogen gene, but not LMW- and HMW-kinino-
gen genes, and that LPS stimulates the expression of
T-kininogen gene. Evidence that rat smooth muscle
cell line A7r5 cells also expressed T-kininogen
mRNA in response to LPS further supports this con-
clusion.
Addition of LPS to the cultured VSMC resulted in
a marked elevation of T-kininogen mRNA in cells in
Fig. 8. Southern blot analysis of cDNA products generated
from rat aortic smooth muscle or VSMC by RT^PCR using
primers and probes speci¢c for tissue kallikreins rKLK10 (A)
and rKLK1 (B). RT^PCR (30 cycles) was performed with total
RNA (1 Wg) extracted from aorta muscle, VSMC or subman-
dibular gland (SMG) using speci¢c primers for rKLK10 (A) or
rKLK1 (B), then Southern blotting of the cDNA products was
carried out using oligonucleotide probe speci¢c for each kallik-
rein. Experiments were carried out with RNA samples from
four animals or cultures, and representative blottings are
shown.
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a similar time-course pro¢le with the in vivo experi-
ments, suggesting that a direct action of LPS on
VSMC induces the expression of T-kininogen gene,
probably via the LPS-receptor CD14 [16]. LPS was
e¡ective in vivo at the dose of 0.5 mg/kg i.v., which
was comparable to the e¡ective concentration of LPS
at 0.5^5 Wg/ml in vitro. Although addition of AII
also produced a marked elevation of T-kininogen
mRNA in cultured VSMC, we could not con¢rm
this AII e¡ect by the in vivo experiments: neither a
bolus i.v. injection of AII (100 ng/animal), a dose
su⁄cient to induce the elevation of blood pressure,
nor a continuous infusion for 24 h at 50 ng/min per
animal, which elevates plasma AII levels by three-
fold, corresponding to about 50 pg/ml plasma [17],
a¡ected T-kininogen mRNA levels in the aorta
muscle. The reason for the discrepancy between the
in vitro and in vivo e¡ects of AII seems to be due to
much higher concentrations of AII in vitro (10^1000
nM) than in vivo. Thus it is doubtful whether the
elevation of blood AII within the physiological range
results in the expression of T-kininogen gene of rat
vessels.
It is well documented that T-kininogen is one of
the acute-phase proteins in the rat, whose synthesis
in the liver increases after induction of in£ammation
[15,18], and IL-6 has been identi¢ed to be a mediator
for this hepatic response [19,20]. However, as shown
in this study, IL-6 was inactive to stimulate T-kini-
nogen synthesis by rat VSMC. Other agents, such as
dexamethasone, Bt2cAMP, IL-1 and TNF, which
have been reported to enhance the expression of
T-kininogen gene in hepatocytes [21] or ¢broblasts
[13], also did not a¡ect T-kininogen synthesis by
VSMC. Like LPS and AII, PMA, a potent activator
of protein kinase C, markedly enhanced the synthesis
of T-kininogen by VSMC. Depletion of the PMA-
sensitive protein kinase C by 24 h pretreatment of
VSMC with PMA abolished not only the PMA e¡ect
on T-kininogen synthesis, but also the e¡ect of AII
or LPS, suggesting that the PMA-sensitive protein
kinase C is involved in the enhanced expression of
T-kininogen gene by these agents. In fact, the AII
e¡ect was clearly inhibited by a protein kinase C
inhibitor H-7, but not by the protein kinase A inhib-
itor H-89 or calmodulin inhibitor W-7. However, in
contrast to AII, the LPS e¡ect on T-kininogen syn-
thesis was uniformly inhibited by these inhibitors.
Thus it is likely that AII stimulates the expression
of T-kininogen gene by a protein kinase C-dependent
pathway in rat VSMC, while the LPS e¡ect may
involve multiple protein kinases, one of which might
be a PMA-sensitive protein kinase C. The fact that
T-kininogen synthesis by VSMC is stimulated by
PMA, but not by IL-6 and Bt2cAMP, suggests that
the regulation of T-kininogen expression is distinct
from that in hepatocytes or ¢broblasts, in terms of
the responsiveness to these agents.
Rats have more than ten members of the tissue
kallikrein family. Of these members, true kallikrein
encoded by rKLK1 has a kininogenase activity to
liberate kinins from LMW- and HMW-kininogens
[1], but not from T-kininogen [22], and T-kininoge-
nase encoded by rKLK10 liberates T-kinin from
T-kininogen [23]. In the rat, vascular tissue contains
a glandular kallikrein that is immunoreactive to anti-
body for rat urinary kallikrein [4] and has a kinino-
genase activity to release kinin from dog kininogen
[3], indicating the presence of true kallikrein in rat
vascular tissue. As expected, mRNA for true kalli-
krein was detectable in the aortic smooth muscle.
However, as shown in this study, mRNA for T-kini-
nogenase was not detectable in either aortic smooth
muscle or cultured VSMC, in contrast to a distinct
signal corresponding to T-kininogenase mRNA in
submandibular gland [23]. Taken together, it appears
that rat VSMC is a source of T-kininogen but not of
T-kininogenase.
In conclusion, we have demonstrated that rat
VSMC express T-kininogen gene but not LMW-
and HMW-kininogen genes. We have also found
that AII and LPS stimulate the expression of T-kini-
nogen gene by VSMC, probably via a PMA-sensitive
protein kinase C or multiple protein kinases includ-
ing protein kinase C, respectively. Further studies
will be needed to demonstrate the physiological
role of T-kininogen in the vascular wall.
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